Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Down 15.3% in February

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 2,050,094 shares, a decline of 15.3% from the January 29th total of 2,419,408 shares. Currently, 5.5% of the company’s stock are sold short. Based on an average daily volume of 329,823 shares, the short-interest ratio is currently 6.2 days. Based on an average daily volume of 329,823 shares, the short-interest ratio is currently 6.2 days. Currently, 5.5% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HOWL shares. Bank of America dropped their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. HC Wainwright lowered their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Finally, Citizens Jmp downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Werewolf Therapeutics has a consensus rating of “Hold” and an average target price of $3.75.

Insider Activity

In related news, Director Luke Evnin sold 108,606 shares of the company’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $0.61, for a total transaction of $66,249.66. Following the completion of the sale, the director owned 2,550,674 shares in the company, valued at approximately $1,555,911.14. This represents a 4.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Ansbert Gadicke sold 83,230 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $0.97, for a total transaction of $80,733.10. Following the completion of the sale, the insider owned 4,784,111 shares of the company’s stock, valued at approximately $4,640,587.67. The trade was a 1.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,128,294 shares of company stock worth $864,401 over the last 90 days. 23.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Quadrature Capital Ltd purchased a new position in shares of Werewolf Therapeutics during the second quarter worth approximately $28,000. Regal Investment Advisors LLC raised its position in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the period. Vontobel Holding Ltd. lifted its stake in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics during the second quarter valued at about $48,000. Finally, AQR Capital Management LLC bought a new position in shares of Werewolf Therapeutics during the first quarter valued at about $79,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

NASDAQ HOWL traded up $0.03 on Wednesday, hitting $0.61. The stock had a trading volume of 156,932 shares, compared to its average volume of 466,591. The firm has a 50-day moving average of $0.64 and a 200-day moving average of $1.10. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics has a 52-week low of $0.53 and a 52-week high of $2.38. The company has a market capitalization of $29.73 million, a price-to-earnings ratio of -0.38 and a beta of 0.78.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.